Cargando…
Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients
Protein tyrosine phosphatase receptor gamma (PTPRG) is a member of the receptor-like family protein tyrosine phosphatases and acts as a tumor suppressor gene in different neoplasms. Recent studies reported the down-regulation of PTPRG expression levels in Chronic Myeloid Leukemia disease (CML). In a...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065106/ https://www.ncbi.nlm.nih.gov/pubmed/33893334 http://dx.doi.org/10.1038/s41598-021-86875-y |
_version_ | 1783682269768056832 |
---|---|
author | Ismail, Mohamed A. Vezzalini, Marzia Morsi, Hisham Abujaber, Ahmad Al Sayab, Ali Siveen, Kodappully Yassin, Mohamed A. Monne, Maria Samara, Muthanna Cook, Richard Sorio, Claudio Modjtahedi, Helmout Al-Dewik, Nader I. |
author_facet | Ismail, Mohamed A. Vezzalini, Marzia Morsi, Hisham Abujaber, Ahmad Al Sayab, Ali Siveen, Kodappully Yassin, Mohamed A. Monne, Maria Samara, Muthanna Cook, Richard Sorio, Claudio Modjtahedi, Helmout Al-Dewik, Nader I. |
author_sort | Ismail, Mohamed A. |
collection | PubMed |
description | Protein tyrosine phosphatase receptor gamma (PTPRG) is a member of the receptor-like family protein tyrosine phosphatases and acts as a tumor suppressor gene in different neoplasms. Recent studies reported the down-regulation of PTPRG expression levels in Chronic Myeloid Leukemia disease (CML). In addition, the BCR-ABL1 transcript level is currently a key predictive biomarker of CML response to treatment with Tyrosine Kinase Inhibitors (TKIs). The aim of this study was to employ flow cytometry to monitor the changes in the expression level of PTPRG in the white blood cells (WBCs) of CML patients at the time of diagnosis and following treatment with TKIs. WBCs from peripheral blood of 21 CML patients were extracted at diagnosis and during follow up along with seven healthy individuals. The PTPRG expression level was determined at protein and mRNA levels by both flow cytometry with monoclonal antibody (TPγ B9-2) and RT-qPCR, and BCR-ABL1 transcript by RT-qPCR, respectively. PTPRG expression was found to be lower in the neutrophils and monocytes of CML patients at time of diagnosis compared to healthy individuals. Treatment with TKIs nilotinib and Imatinib Mesylate restored the expression of PTPRG in the WBCs of CML patients to levels observed in healthy controls. Moreover, restoration levels were greatest in optimal responders and occurred earlier with nilotinib compared to imatinib. Our results support the measurement of PTPRG expression level in the WBCs of CML patients by flow cytometry as a monitoring tool for the response to treatment with TKIs in CML patients. |
format | Online Article Text |
id | pubmed-8065106 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-80651062021-04-27 Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients Ismail, Mohamed A. Vezzalini, Marzia Morsi, Hisham Abujaber, Ahmad Al Sayab, Ali Siveen, Kodappully Yassin, Mohamed A. Monne, Maria Samara, Muthanna Cook, Richard Sorio, Claudio Modjtahedi, Helmout Al-Dewik, Nader I. Sci Rep Article Protein tyrosine phosphatase receptor gamma (PTPRG) is a member of the receptor-like family protein tyrosine phosphatases and acts as a tumor suppressor gene in different neoplasms. Recent studies reported the down-regulation of PTPRG expression levels in Chronic Myeloid Leukemia disease (CML). In addition, the BCR-ABL1 transcript level is currently a key predictive biomarker of CML response to treatment with Tyrosine Kinase Inhibitors (TKIs). The aim of this study was to employ flow cytometry to monitor the changes in the expression level of PTPRG in the white blood cells (WBCs) of CML patients at the time of diagnosis and following treatment with TKIs. WBCs from peripheral blood of 21 CML patients were extracted at diagnosis and during follow up along with seven healthy individuals. The PTPRG expression level was determined at protein and mRNA levels by both flow cytometry with monoclonal antibody (TPγ B9-2) and RT-qPCR, and BCR-ABL1 transcript by RT-qPCR, respectively. PTPRG expression was found to be lower in the neutrophils and monocytes of CML patients at time of diagnosis compared to healthy individuals. Treatment with TKIs nilotinib and Imatinib Mesylate restored the expression of PTPRG in the WBCs of CML patients to levels observed in healthy controls. Moreover, restoration levels were greatest in optimal responders and occurred earlier with nilotinib compared to imatinib. Our results support the measurement of PTPRG expression level in the WBCs of CML patients by flow cytometry as a monitoring tool for the response to treatment with TKIs in CML patients. Nature Publishing Group UK 2021-04-23 /pmc/articles/PMC8065106/ /pubmed/33893334 http://dx.doi.org/10.1038/s41598-021-86875-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Ismail, Mohamed A. Vezzalini, Marzia Morsi, Hisham Abujaber, Ahmad Al Sayab, Ali Siveen, Kodappully Yassin, Mohamed A. Monne, Maria Samara, Muthanna Cook, Richard Sorio, Claudio Modjtahedi, Helmout Al-Dewik, Nader I. Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients |
title | Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients |
title_full | Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients |
title_fullStr | Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients |
title_full_unstemmed | Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients |
title_short | Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients |
title_sort | predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065106/ https://www.ncbi.nlm.nih.gov/pubmed/33893334 http://dx.doi.org/10.1038/s41598-021-86875-y |
work_keys_str_mv | AT ismailmohameda predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT vezzalinimarzia predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT morsihisham predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT abujaberahmad predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT alsayabali predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT siveenkodappully predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT yassinmohameda predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT monnemaria predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT samaramuthanna predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT cookrichard predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT sorioclaudio predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT modjtahedihelmout predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT aldewiknaderi predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients |